Skip Navigation

Journal of Tropical Pediatrics 2002 48(5):300-302; doi:10.1093/tropej/48.5.300
© 2002 by Oxford University Press
This Article
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Mascarenhas, J. D. P.
Right arrow Articles by Linhares, A. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mascarenhas, J. D. P.
Right arrow Articles by Linhares, A. C.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Brief Report

Tetravalent Rhesus-human Rotavirus Vaccine (RRV-TV) in Belém, Brazil: Efficacy against Prevailing P and G Genotypes

J. D. P. Mascarenhas1, J. P. G. Leite2, Y. B. Gabbay1, M. L. Almeida3 and A. C. Linhares1

1 Instituto Evandro Chagas, Fundação Nacional de Saúde, Belém, Pará, Brazil 2 Departmento de Virologia, Instituto Oswaldo Cruz, Rio de Janeiro, Brazil 3 Ex-bolsista do Conselho Nacional de Desenvolvimento Cientifíco e Tecnológico, PIBIC/IEC, Brazil

To determine the efficacy of a reassortant rhesus-human tetravalent rotavirus vaccine (RRV-TV) (4 x 104 pfu/dose) against P and G rotavirus genotypes, 90 positive samples were tested using reverse transcription-polymerase chain reaction. The efficacy of the RRV-TV vaccine against P[8] and G1 individually or in binary combination P[8], G1 was 72 per cent (p < 0.005) 61 per cent (p < 0.013), and 70 per cent (p < 0.009), respectively, only for the first year of follow-up. In the second year, as well as after 2 years of follow-up, no efficacy was observed to these genotypes. These data indicate that further studies with rotavirus vaccines should focus on the molecular characterization of rotaviruses genotypes, in order to see whether or not cross-protection among different G and P genotypes may occur as a result of common bearing of VP4 specificities.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.